Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 832

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Is there new hope for therapeutic matrix metalloproteinase inhibition?

Vandenbroucke, Roosmarijn E., Libert, Claude·2014·Nature Reviews Drug Discovery
DOI 10.1038/nrd4390
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd4390

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 293

  1. Gialeli, C., Theocharis, A. D. & Karamanos, N. K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 278, 16–27 (2011). · DOI · Paper page
  2. Davies, B., Brown, P. D., East, N., Crimmin, M. J. & Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53, 2087–2091 (1993).
  3. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002). · DOI · Paper page
  4. Fisher, J. F. & Mobashery, S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev. 25, 115–136 (2006). · DOI · Paper page
  5. Overall, C. M. & Kleifeld, O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br. J. Cancer 94, 941–946 (2006). · DOI · Paper page
  6. Overall, C. M. & Kleifeld, O. Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Rev. Cancer 6, 227–239 (2006). · DOI · Paper page
  7. Pirard, B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov. Today 12, 640–646 (2007). · DOI
  8. Rao, B. G. Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr. Pharm. Design 11, 295–322 (2005). · DOI
  9. Pavlaki, M. & Zucker, S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 22, 177–203 (2003). · DOI
  10. Iyer, R. P., Patterson, N. L., Fields, G. B. & Lindsey, M. L. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am. J. Physiol. Heart Circ. Physiol. 303, H919–H930 (2012). · DOI
  11. Hadler-Olsen, E., Winberg, J. O. & Uhlin-Hansen, L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 34, 2041–2051 (2013). · DOI · Paper page
  12. Decock, J., Thirkettle, S., Wagstaff, L. & Edwards, D. R. Matrix metalloproteinases: protective roles in cancer. J. Cell. Mol. Med. 15, 1254–1265 (2011). · DOI
  13. Lopez-Otin, C., Palavalli, L. H. & Samuels, Y. Protective roles of matrix metalloproteinases: from mouse models to human cancer. Cell Cycle 8, 3657–3662 (2009). · DOI
  14. Vanlaere, I. & Libert, C. Matrix metalloproteinases as drug targets in infections caused by Gram-negative bacteria and in septic shock. Clin. Microbiol. Rev. 22, 224–239 (2009). · DOI
  15. Drummond, A. H. et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY Acad. Sci. 878, 228–235 (1999). · DOI
  16. Skiles, J. W., Gonnella, N. C. & Jeng, A. Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. 11, 2911–2977 (2004). · DOI
  17. Edwards, D. R., Handsley, M. M. & Pennington, C. J. The ADAM metalloproteinases. Mol. Aspects Med. 29, 258–289 (2008). · DOI · Paper page
  18. Tan Ide, A., Ricciardelli, C. & Russell, D. L. The metalloproteinase ADAMTS1: a comprehensive review of its role in tumorigenic and metastatic pathways. Int. J. Cancer 133, 2263–2276 (2013). · DOI
  19. Gross, J. & Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014–1022 (1962). · DOI · Paper page
  20. Sterchi, E. E. Special issue: metzincin metalloproteinases. Mol. Aspects Med. 29, 255–257 (2008). · DOI
  21. Ra, H. J. & Parks, W. C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587–596 (2007). · DOI · Paper page
  22. Fanjul-Fernandez, M., Folgueras, A. R., Cabrera, S. & Lopez-Otin, C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim. Biophys. Acta 1803, 3–19 (2010). · DOI · Paper page
  23. Butler, G. S. & Overall, C. M. Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nature Rev. Drug Discov. 8, 935–948 (2009). · DOI
  24. Sorokin, L. The impact of the extracellular matrix on inflammation. Nature Rev. Immunol. 10, 712–723 (2010). · DOI · Paper page
  25. Cauwe, B., Van den Steen, P. E. & Opdenakker, G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42, 113–185 (2007). · DOI · Paper page
  26. Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nature Rev. Mol. Cell Biol. 8, 221–233 (2007). · DOI · Paper page
  27. Loffek, S., Schilling, O. & Franzke, C. W. Series “matrix metalloproteinases in lung health and disease”: biological role of matrix metalloproteinases: a critical balance. Eur. Respir. J. 38, 191–208 (2011). · DOI · Paper page
  28. Troeberg, L. & Nagase, H. Analysis of TIMP expression and activity. Methods Mol. Med. 135, 251–267 (2007). · DOI
  29. Nagase, H., Visse, R. & Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Res. 69, 562–573 (2006). · DOI · Paper page
  30. Murphy, G. Tissue inhibitors of metalloproteinases. Genome Biol. 12, 233 (2011). · DOI · Paper page
  31. Leco, K. J. et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J. Clin. Invest. 108, 817–829 (2001). · DOI
  32. Fata, J. E. et al. Accelerated apoptosis in the Timp-3-deficient mammary gland. J. Clin. Invest. 108, 831–841 (2001). · DOI
  33. Mohammed, F. F. et al. Abnormal TNF activity in Timp3−/− mice leads to chronic hepatic inflammation and failure of liver regeneration. Nature Genet. 36, 969–977 (2004). · DOI · Paper page
  34. Whittaker, M., Floyd, C. D., Brown, P. & Gearing, A. J. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99, 2735–2776 (1999). · DOI · Paper page
  35. Verma, R. P. Hydroxamic acids as matrix metalloproteinase inhibitors. EXS 103, 137–176 (2012).
  36. Macaulay, V. M. et al. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res. 5, 513–520 (1999).
  37. Acharya, M. R., Venitz, J., Figg, W. D. & Sparreboom, A. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist. Updat. 7, 195–208 (2004). · DOI
  38. Eccles, S. A. et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res. 56, 2815–2822 (1996).
  39. Sledge, G. W. et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl Cancer Inst. 87, 1546–1550 (1995). · DOI
  40. Low, J. A., Johnson, M. D., Bone, E. A. & Dickson, R. B. The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res. 2, 1207–1214 (1996).
  41. Watson, S. A. et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 55, 3629–3633 (1995).
  42. Chirivi, R. G. et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer 58, 460–464 (1994). · DOI
  43. Taraboletti, G. et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl Cancer Inst. 87, 293–298 (1995). · DOI
  44. Mannello, F., Tonti, G. & Papa, S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets 5, 285–298 (2005). · DOI
  45. Vihinen, P., Ala-aho, R. & Kahari, V. M. Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Targets 5, 203–220 (2005). · DOI · Paper page
  46. Sparano, J. A. et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J. Clin. Oncol. 22, 4683–4690 (2004). · DOI · Paper page
  47. Goffin, J. R. et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 11, 3417–3424 (2005). · DOI
  48. Fingleton, B. MMPs as therapeutic targets — still a viable option? Semin. Cell Dev. Biol. 19, 61–68 (2008). · DOI · Paper page
  49. Fingleton, B. Matrix metalloproteinases: roles in cancer and metastasis. Front. Biosci. 11, 479–491 (2006). · DOI · Paper page
  50. Kruger, A., Kates, R. E. & Edwards, D. R. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim. Biophys. Acta 1803, 95–102 (2010). · DOI
  51. Eatock, M. et al. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother. Pharmacol. 55, 39–46 (2005). · DOI
  52. Hoekstra, R., Eskens, F. A. & Verweij, J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncol. 6, 415–427 (2001). · DOI
  53. Close, D. R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis. 60, iii62–iii67 (2001). · DOI
  54. Li, J., et al. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 15, 4961–4966 (2005). · DOI
  55. de Melo, E. B. A QSAR study of matrix metalloproteinases type 2 (MMP-2) inhibitors with cinnamoyl pyrrolidine derivatives. Scientia pharmaceutica 80, 265–281 (2012). · DOI
  56. Jacobsen, J. A., Major Jourden, J. L., Miller, M. T. & Cohen, S. M. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim. Biophys. Acta 1803, 72–94 (2010). · DOI · Paper page
  57. Naglich, J. G. et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 61, 8480–8485 (2001).
  58. Miller, K. D. et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin. Cancer Res. 10, 1971–1975 (2004). · DOI
  59. Leighl, N. B. et al. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J. Clin. Oncol. 23, 2831–2839 (2005). · DOI
  60. Lutz, J. et al. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 79, 655–661 (2005). · DOI
  61. Lee, M. et al. Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl) thiiranes as selective gelatinase inhibitors. Org. Lett. 7, 4463–4465 (2005). · DOI
  62. Ikejiri, M. et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J. Biol. Chem. 280, 33992–34002 (2005). · DOI
  63. Ikejiri, M. et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J. Org. Chem. 70, 5709–5712 (2005). · DOI
  64. Grams, F. et al. Pyrimidine-2,4,6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol. Chem. 382, 1277–1285 (2001). · DOI
  65. Lein, M. et al. The new synthetic matrix metalloproteinase inhibitor (Roche 28–2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21, 2089–2096 (2002). · DOI
  66. Abramjuk, C. et al. Matrix metalloproteinase inhibitor Ro 28–2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats. Anticancer Drugs 16, 855–861 (2005). · DOI · Paper page
  67. Kilian, M. et al. Matrix metalloproteinase inhibitor RO 28–2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot. Essent. Fatty Acids 75, 429–434 (2006). · DOI · Paper page
  68. Maquoi, E. et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin. Cancer Res. 10, 4038–4047 (2004). · DOI
  69. De Savi, C. et al. Hydantoin based inhibitors of MMP13 — discovery of AZD6605. Bioorg. Med. Chem. Lett. 23, 4705–4712 (2013). · DOI
  70. Hu, Y. et al. Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. 13, 6629–6644 (2005). · DOI
  71. Li, J. et al. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 15, 4961–4966 (2005). · DOI
  72. Wu, J. et al. Identification of potent and selective MMP-13 inhibitors. Bioorg. Med. Chem. Lett. 15, 4105–4109 (2005). · DOI
  73. Dive, V. et al. Phosphinic peptides as zinc metalloproteinase inhibitors. Cell. Mol. Life Sci. 61, 2010–2019 (2004). · DOI
  74. Reiter, L. A. et al. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg. Med. Chem. Lett. 13, 2331–2336 (2003). · DOI
  75. Dive, V. et al. Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases. Int. J. Cancer 113, 775–781 (2005). · DOI
  76. Sorsa, T. et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann. Med. 38, 306–321 (2006). · DOI · Paper page
  77. Rudek, M. A. et al. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 19, 584–592 (2001). · DOI
  78. Schechter, I. & Berger, A. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem. Biophys. Res. Commun. 32, 898–902 (1968). · DOI
  79. Aureli, L. et al. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr. Med. Chem. 15, 2192–2222 (2008). · DOI
  80. Park, H. I. et al. The intermediate S1′ pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J. Biol. Chem. 278, 51646–51653 (2003). · DOI
  81. Gupta, S. P. & Patil, V. M. Specificity of binding with matrix metalloproteinases. EXS 103, 35–56 (2012).
  82. Gupta, S. P. Matrix metalloproteinase inhibitors: specificity of binding and structure-activity relationships. EXS 103, v–vi (2012).
  83. Gege, C. et al. Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. J. Med. Chem. 55, 709–716 (2012). · DOI
  84. Jungel, A. et al. Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann. Rheum. Dis. 69, 898–902 (2010). · DOI
  85. Schnute, M. E. et al. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. Bioorg. Med. Chem. Lett. 20, 576–580 (2010). · DOI
  86. Fabre, B. et al. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily. Chembiochem. 15, 399–412 (2014). · DOI
  87. Roth, J. et al. Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg. Med. Chem. Lett. 21, 7180–7184 (2011). · DOI
  88. Udi, Y. et al. Unraveling hidden regulatory sites in structurally homologous metalloproteases. J. Mol. Biol. 425, 2330–2346 (2013). · DOI
  89. Ndinguri, M. W., Bhowmick, M., Tokmina-Roszyk, D., Robichaud, T. K. & Fields, G. B. Peptide-based selective inhibitors of matrix metalloproteinase-mediated activities. Molecules 17, 14230–14248 (2012). · DOI
  90. Koivunen, E. et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotech. 17, 768–774 (1999). · DOI · Paper page
  91. Suojanen, J., Salo, T., Koivunen, E., Sorsa, T. & Pirila, E. A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth. Cancer Biol. Ther. 8, 2362–2370 (2009). · DOI
  92. Devy, L. & Dransfield, D. T. New strategies for the next generation of matrix-metalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem. Res. Int. 2011, 191670 (2011). · DOI
  93. Hoet, R. M. et al. Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nature Biotech. 23, 344–348 (2005). · DOI · Paper page
  94. Devy, L. et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69, 1517–1526 (2009). · DOI · Paper page
  95. Ingvarsen, S. et al. Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis. J. Biol. Chem. 288, 10195–10204 (2013). · DOI
  96. Kaimal, R. et al. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res. 73, 2457–2467 (2013). · DOI
  97. Basu, B. et al. Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. Int. J. Biochem. Cell Biol. 44, 393–403 (2012). · DOI
  98. Hu, J., Van den Steen, P. E., Houde, M., Ilenchuk, T. T. & Opdenakker, G. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochem. Pharmacol. 67, 1001–1009 (2004). · DOI
  99. Martens, E. et al. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim. Biophys. Acta 1770, 178–186 (2007). · DOI
  100. Shiryaev, S. A. et al. A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP. Oncogenesis 2, e80 (2013). · DOI · Paper page
  101. Sela-Passwell, N. et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nature Med. 18, 143–147 (2012). · DOI
  102. Naito, S. et al. Development of a neutralizing antibody specific for the active form of matrix metalloproteinase-13. Biochemistry 51, 8877–8884 (2012). · DOI
  103. Bu, Z. et al. SZ-117, a monoclonal antibody against matrix metalloproteinase-2 inhibits tumor cell-mediated angiogenesis. Hybridoma 31, 63–67 (2012). · DOI
  104. Tchetverikov, I. et al. Active MMPs captured by alpha 2 macroglobulin as a marker of disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol 21, 711–718 (2003).
  105. Etique, N., Verzeaux, L., Dedieu, S. & Emonard, H. LRP-1: a checkpoint for the extracellular matrix proteolysis. BioMed Res. Int. 2013, 152163 (2013). · DOI
  106. Birkenmeier, G. et al. Polymyxin B-conjugated α2-macroglobulin as an adjunctive therapy to sepsis: modes of action and impact on lethality. J. Pharmacol. Exp. Ther. 318, 762–771 (2006). · DOI
  107. Webb, D. J. & Gonias, S. L. A modified human alpha 2-macroglobulin derivative that binds tumor necrosis factor-alpha and interleukin-1 beta with high affinity in vitro and reverses lipopolysaccharide toxicity in vivo in mice. Lab. Invest. 78, 939–948 (1998).
  108. Amour, A. et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473, 275–279 (2000). · DOI · Paper page
  109. Smookler, D. S. et al. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J. Immunol. 176, 721–725 (2006). · DOI
  110. Vanhoutte, D. & Heymans, S. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'. J. Mol. Cell Cardiol. 48, 445–453 (2010). · DOI
  111. Moore, C. S. & Crocker, S. J. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am. J. Pathol. 180, 12–16 (2012). · DOI
  112. Stetler-Stevenson, W. G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 1, re6 (2008). · DOI · Paper page
  113. Seo, D. W. et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114, 171–180 (2003). · DOI
  114. Stetler-Stevenson, W. G. & Seo, D. W. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol. Med. 11, 97–103 (2005). · DOI
  115. Nieuwesteeg, M. A., Walsh, L. A., Fox, M. A. & Damjanovski, S. Domain specific overexpression of TIMP-2 and TIMP-3 reveals MMP-independent functions of TIMPs during Xenopus laevis development. Biochem. Cell Biol. 90, 585–595 (2012). · DOI
  116. Butler, G. S. et al. The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 273, 871–880 (1998). · DOI · Paper page
  117. Hu, J., Van den Steen, P. E., Sang, Q. X. & Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Rev. Drug Discov. 6, 480–498 (2007). · DOI · Paper page
  118. Qiu, Z., Hu, J., Van den Steen, P. E. & Opdenakker, G. Targeting matrix metalloproteinases in acute inflammatory shock syndromes. Comb. Chem. High Throughput Screen. 15, 555–570 (2012). · DOI
  119. Vandenbroucke, R. E., Dejonckheere, E. & Libert, C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur. Respir. J. 38, 1200–1214 (2011). · DOI
  120. Dejonckheere, E., Vandenbroucke, R. E. & Libert, C. Matrix metalloproteinases as drug targets in ischemia/reperfusion injury. Drug Discov. Today 16, 762–778 (2011).
  121. Newby, A. C. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul. Pharmacol. 56, 232–244 (2012). · DOI
  122. Yabluchanskiy, A., Ma, Y., Iyer, R. P., Hall, M. E. & Lindsey, M. L. Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology 28, 391–403 (2013). · DOI · Paper page
  123. Halade, G. V., Jin, Y. F. & Lindsey, M. L. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol. Ther. 139, 32–40 (2013). · DOI · Paper page
  124. Nissinen, L. & Kahari, V. M. Matrix metalloproteinases in inflammation. Biochim. Biophys. Acta 1840, 2571–2580 (2014). · DOI · Paper page
  125. Angus, D. C. & van der Poll, T. Severe sepsis and septic shock. N. Engl. J. Med. 369, 2063 (2013). · DOI · Paper page
  126. Marti-Carvajal, A. J., Sola, I., Gluud, C., Lathyris, D. & Cardona, A. F. Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst. Rev. 12, CD004388 (2012).
  127. Deutschman, C. S. Steroid responses in sepsis: some novel thinking that may provide new insight. Crit. Care 17, 147 (2013). · DOI
  128. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507–3512 (2013). · DOI · Paper page
  129. Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 19, 198–208 (2011). · DOI · Paper page
  130. Okamoto, T. et al. Activation of human matrix metalloproteinases by various bacterial proteinases. J. Biol. Chem. 272, 6059–6066 (1997). · DOI
  131. Elkington, P. T., Green, J. A. & Friedland, J. S. Analysis of matrix metalloproteinase secretion by macrophages. Methods Mol. Biol. 531, 253–265 (2009). · DOI
  132. Lalu, M. M., Cena, J., Chowdhury, R., Lam, A. & Schulz, R. Matrix metalloproteinases contribute to endotoxin and interleukin-1β induced vascular dysfunction. Br. J. Pharmacol. 149, 31–42 (2006). · DOI
  133. Dubois, B. et al. Gelatinase B deficiency protects against endotoxin shock. Eur. J. Immunol. 32, 2163–2171 (2002). · DOI
  134. Barichello, T. et al. Inhibition of matrix metalloproteinases-2 and -9 prevents cognitive impairment induced by pneumococcal meningitis in Wistar rats. Exp. Biol. Med. 239, 225–231 (2014). · DOI
  135. Pagenstecher, A., Stalder, A. K., Kincaid, C. L., Volk, B. & Campbell, I. L. Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am. J. Pathol. 157, 197–210 (2000). · DOI
  136. Rahman, M. et al. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis. Inflamm. Res. 61, 571–579 (2012). · DOI
  137. Chen, J. et al. Biodistribution of radiolabeled [(3)H] CMT-3 in rats. Curr. Med. Chem. 8, 253–256 (2001). · DOI
  138. Liu, Y. et al. The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). Curr. Med. Chem. 8, 243–252 (2001). · DOI
  139. Steinberg, J. et al. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J. Surg. Res. 111, 185–195 (2003). · DOI
  140. Vandooren, J., Van den Steen, P. E. & Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol. 48, 222–272 (2013). · DOI · Paper page
  141. Muhl, D. et al. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J. Crit. Care 26, 550–555 (2011). · DOI
  142. Maitra, S. R., Jacob, A., Zhou, M. & Wang, P. Modulation of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in sepsis. Int. J. Clin. Exp. Med. 3, 180–185 (2010).
  143. Hu, J., Van den Steen, P. E., Dillen, C. & Opdenakker, G. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochem. Pharmacol. 70, 535–544 (2005). · DOI
  144. Renckens, R. et al. Matrix metalloproteinase-9 deficiency impairs host defense against abdominal sepsis. J. Immunol. 176, 3735–3741 (2006). · DOI · Paper page
  145. Dal-Pizzol, F. et al. Matrix metalloproteinase-2 and metalloproteinase-9 activities are associated with blood-brain barrier dysfunction in an animal model of severe sepsis. Mol. Neurobiol. 48, 62–70 (2013). · DOI
  146. Tressel, S. L. et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol. Med. 3, 370–384 (2011). · DOI
  147. Schouten, M., Wiersinga, W. J., Levi, M. & van der Poll, T. Inflammation, endothelium, and coagulation in sepsis. J. Leukoc. Biol. 83, 536–545 (2008). · DOI · Paper page
  148. Vandenbroucke, R. E., Dejager, L. & Libert, C. The first MMP in sepsis. EMBO Mol. Med. 3, 367–369 (2011). · DOI
  149. Fanjul-Fernandez, M. et al. Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J. Biol. Chem. 288, 14647–14656 (2013). · DOI
  150. Van Lint, P. & Libert, C. Matrix metalloproteinase-8: cleavage can be decisive. Cytokine Growth Factor Rev. 17, 217–223 (2006). · DOI
  151. Dejonckheere, E., Vandenbroucke, R. E. & Libert, C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine Growth Factor Rev. 22, 73–81 (2011). · DOI
  152. Tester, A. M. et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2, e312 (2007). · DOI
  153. Lauhio, A. et al. Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol. Res. 64, 590–594 (2011). · DOI
  154. Solan, P. D. et al. A novel role for matrix metalloproteinase-8 in sepsis. Crit. Care Med. 40, 379–387 (2012). · DOI
  155. Punyadeera, C. et al. A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. J. Emerg. Trauma Shock 3, 26–35 (2010). · DOI
  156. Hoffmann, U., Brueckmann, M. & Borggrefe, M. Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis? Crit. Care 13, 1006 (2009). · DOI
  157. Vandenbroucke, R. E. et al. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J. Neurosci. 32, 9805–9816 (2012). · DOI
  158. Gonzalez-Lopez, A. et al. MMP-8 deficiency increases TLR/RAGE ligands S100A8 and S100A9 and exacerbates lung inflammation during endotoxemia. PLoS ONE 7, e39940 (2012). · DOI
  159. Singh, A. et al. Collagenase-3 (MMP-13) deficiency protects C57BL/6 mice from antibody-induced arthritis. Arthritis Res. Ther. 15, R222 (2013). · DOI
  160. Toriseva, M. et al. MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability. PLoS ONE 7, e42596 (2012). · DOI
  161. Li, N. G., Tang, Y. P. & Duan, J. A. New selective inhibitors of MMP-13 for inflammatory diseases: a patent evaluation (W02012151158). Expert Opin. Ther. Pat. 23, 669–675 (2013). · DOI
  162. Muddasani, P., Norman, J. C., Ellman, M., van Wijnen, A. J. & Im, H. J. Basic fibroblast growth factor activates the MAPK and NFκB pathways that converge on Elk-1 to control production of matrix metalloproteinase-13 by human adult articular chondrocytes. J. Biol. Chem. 282, 31409–31421 (2007). · DOI
  163. Ahmad, R., Sylvester, J. & Zafarullah, M. MyD88, IRAK1 and TRAF6 knockdown in human chondrocytes inhibits interleukin-1-induced matrix metalloproteinase-13 gene expression and promoter activity by impairing MAP kinase activation. Cell Signal. 19, 2549–2557 (2007). · DOI
  164. Vandenbroucke, R. E. et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF. EMBO Mol. Med. 5, 932–948 (2013). · DOI
  165. Carrico, C. J., Meakins, J. L., Marshall, J. C., Fry, D. & Maier, R. V. Multiple-organ-failure syndrome. Arch. Surg. 121, 196–208 (1986). · DOI · Paper page
  166. Deitch, E. A. & Berg, R. Bacterial translocation from the gut: a mechanism of infection. J. Burn Care Rehabil. 8, 475–482 (1987). · DOI
  167. Gearing, A. J. et al. Matrix metalloproteinases and processing of pro-TNF-α. J. Leukoc. Biol. 57, 774–777 (1995). · DOI
  168. Chandler, S., Cossins, J., Lury, J. & Wells, G. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-α fusion protein. Biochem. Biophys. Res. Commun. 228, 421–429 (1996). · DOI · Paper page
  169. d'Ortho, M. P. et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur. J. Biochem. 250, 751–757 (1997). · DOI · Paper page
  170. Tam, E. M., Morrison, C. J., Wu, Y. I., Stack, M. S. & Overall, C. M. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl Acad. Sci. USA 101, 6917–6922 (2004). · DOI · Paper page
  171. Becker-Pauly, C. & Rose-John, S. TNFα cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis. EMBO Mol. Med. 5, 902–904 (2013). · DOI
  172. Marchenko, G. N. & Strongin, A. Y. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene 265, 87–93 (2001). · DOI
  173. Vandenbroucke, R. E. et al. Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation. Mucosal Immunol. 7, 579–588 (2014). · DOI
  174. Gaddnas, F. P. et al. Matrix-metalloproteinase-2, -8 and -9 in serum and skin blister fluid in patients with severe sepsis. Crit. Care 14, R49 (2010). · DOI
  175. MacDonald, T. T., Monteleone, I., Fantini, M. C. & Monteleone, G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140, 1768–1775 (2011). · DOI · Paper page
  176. Giuffrida, P., Biancheri, P. & Macdonald, T. T. Proteases and small intestinal barrier function in health and disease. Curr. Opin. Gastroenterol. 30, 147–153 (2014). · DOI
  177. Medina, C. & Radomski, M. W. Role of matrix metalloproteinases in intestinal inflammation. J. Pharmacol. Exp. Ther. 318, 933–938 (2006). · DOI
  178. Pedersen, J., Coskun, M., Soendergaard, C., Salem, M. & Nielsen, O. H. Inflammatory pathways of importance for management of inflammatory bowel disease. World J. Gastroenterol. 20, 64–77 (2014). · DOI
  179. Billiet, T., Rutgeerts, P., Ferrante, M., Van Assche, G. & Vermeire, S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin. Biol. Ther. 14, 75–101 (2014). · DOI
  180. Podolsky, D. K. Beyond tumor necrosis factor: next-generation biologic therapy for inflammatory bowel disease. Dig. Dis. 27, 366–369 (2009). · DOI
  181. Morgan, A. R. et al. Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. Hum. Immunol. 72, 1117–1127 (2011). · DOI
  182. Sykes, A. P. et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment. Pharmacol. Ther. 13, 1535–1542 (1999). · DOI
  183. Di Sebastiano, P. et al. Beneficial effects of batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 63, 234–239 (2001). · DOI
  184. Gingras, D. et al. Neovastat — a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14, 91–96 (2003). · DOI
  185. Gingras, D., Batist, G. & Beliveau, R. AE-941 (neovastat): a novel multifunctional antiangiogenic compound. Expert Rev. Anticancer Ther. 1, 341–347 (2001). · DOI
  186. Mao, J. W., He, X. M., Tang, H. Y. & Wang, Y. D. Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats. World J. Gastroenterol. 18, 7063–7069 (2012). · DOI
  187. Huang, T. Y. et al. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol. Appl. Pharmacol. 237, 69–82 (2009). · DOI
  188. Wang, Y. D. & Wang, W. Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. World J. Gastroenterol. 14, 5683–5688 (2008). · DOI
  189. Naito, Y. et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm. Res. 53, 462–468 (2004). · DOI
  190. Medina, C. et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284, G116–G122 (2003). · DOI
  191. Rath, T. et al. Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand. J. Gastroenterol. 45, 1186–1196 (2010). · DOI
  192. von Lampe, B., Barthel, B., Coupland, S. E., Riecken, E. O. & Rosewicz, S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47, 63–73 (2000). · DOI · Paper page
  193. Lakatos, G. et al. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig. Dis. 30, 289–295 (2012). · DOI
  194. Koelink, P. J. et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 63, 578–587 (2014). · DOI
  195. Santana, A. et al. Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J. Gastroenterol. 12, 6464–6472 (2006). · DOI
  196. Castaneda, F. E. et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 129, 1991–2008 (2005). · DOI · Paper page
  197. Liu, H. et al. Constitutive expression of MMP9 in intestinal epithelium worsens murine acute colitis and is associated with increased levels of proinflammatory cytokine Kc. Am. J. Physiol. Gastrointest. Liver Physiol. 304, G793–G803 (2013). · DOI
  198. Ishida, K. et al. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J. Pharmacol. Exp. Ther. 324, 422–426 (2008). · DOI
  199. Rodrigues, D. M. et al. Matrix metalloproteinase 9 contributes to gut microbe homeostasis in a model of infectious colitis. BMC Microbiol. 12, 105 (2012). · DOI
  200. Garg, P. et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J. Immunol. 177, 4103–4112 (2006). · DOI

200 of 293 shown

Cited by

See all 832

Metadata

Authors
Vandenbroucke, R. E., & Libert, C.
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2014-11-07
Volume
13
Issue
12
Pages
904-927
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
DOI
10.1038/nrd4390
OpenAlex
W2015375238
Cited by
832
References
10
FWCI
5.14
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.